News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
803,286 Results
Type
Article (78105)
Company Profile (505)
Press Release (724658)
Multimedia
Podcasts (165)
Webinars (26)
Section
Business (213185)
Career Advice (3705)
Deals (37697)
Drug Delivery (139)
Drug Development (88495)
Employer Resources (191)
FDA (18104)
Job Trends (16523)
News (370262)
Policy (37933)
Tag
Academia (2994)
Academic (1)
Accelerated approval (18)
Adcomms (35)
Allergies (128)
Alliances (54732)
ALS (147)
Alzheimer's disease (1687)
Antibody-drug conjugate (ADC) (260)
Approvals (18138)
Artificial intelligence (478)
Autoimmune disease (96)
Automation (29)
Bankruptcy (389)
Best Places to Work (12454)
BIOSECURE Act (23)
Biosimilars (166)
Biotechnology (346)
Bladder cancer (138)
Brain cancer (53)
Breast cancer (516)
Cancer (4091)
Cardiovascular disease (355)
Career advice (3168)
Career pathing (38)
CAR-T (252)
CDC (57)
Cell therapy (698)
Cervical cancer (32)
Clinical research (73471)
Collaboration (1431)
Company closure (4)
Compensation (944)
Complete response letters (61)
COVID-19 (2957)
CRISPR (84)
C-suite (610)
Cystic fibrosis (140)
Data (4779)
Decentralized trials (2)
Denatured (57)
Depression (112)
Diabetes (458)
Diagnostics (7000)
Digital health (36)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (225)
Drug pricing (194)
Drug shortages (36)
Duchenne muscular dystrophy (205)
Earnings (85942)
Editorial (55)
Employer branding (24)
Employer resources (164)
Events (126169)
Executive appointments (992)
FDA (20655)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1287)
Gene editing (177)
Generative AI (44)
Gene therapy (559)
GLP-1 (1028)
Government (5292)
Grass and pollen (8)
Guidances (370)
Healthcare (20596)
HIV (47)
Huntington's disease (40)
IgA nephropathy (64)
Immunology and inflammation (253)
Immuno-oncology (22)
Indications (58)
Infectious disease (3207)
Inflammatory bowel disease (191)
Inflation Reduction Act (16)
Influenza (102)
Intellectual property (196)
Interviews (724)
IPO (17373)
IRA (59)
Job creations (4473)
Job search strategy (2566)
Kidney cancer (16)
Labor market (77)
Layoffs (631)
Leadership (37)
Legal (9292)
Liver cancer (92)
Longevity (12)
Lung cancer (589)
Lymphoma (271)
Machine learning (32)
Management (63)
Manufacturing (655)
MASH (145)
Medical device (14614)
Medtech (14639)
Mergers & acquisitions (21235)
Metabolic disorders (1172)
Multiple sclerosis (140)
NASH (23)
Neurodegenerative disease (234)
Neuropsychiatric disorders (62)
Neuroscience (2746)
NextGen: Class of 2025 (7421)
Non-profit (5077)
Now hiring (54)
Obesity (568)
Opinion (315)
Ovarian cancer (140)
Pain (171)
Pancreatic cancer (176)
Parkinson's disease (243)
Partnered (30)
Patents (426)
Patient recruitment (334)
Peanut (57)
People (62908)
Pharmaceutical (94)
Pharmacy benefit managers (29)
Phase I (22723)
Phase II (31979)
Phase III (24135)
Pipeline (2809)
Policy (300)
Postmarket research (3255)
Preclinical (10187)
Press Release (72)
Prostate cancer (203)
Psychedelics (52)
Radiopharmaceuticals (281)
Rare diseases (696)
Real estate (6806)
Recruiting (77)
Regulatory (27057)
Reports (53)
Research institute (2683)
Resumes & cover letters (588)
Rett syndrome (16)
RNA editing (15)
RSV (76)
Schizophrenia (140)
Series A (213)
Series B (159)
Service/supplier (19)
Sickle cell disease (81)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (41)
Startups (3964)
State (2)
Stomach cancer (17)
Supply chain (102)
Tariffs (96)
The Weekly (106)
Vaccines (1052)
Venture capital (67)
Weight loss (399)
Women's health (59)
Worklife (21)
Date
Today (198)
Last 7 days (787)
Last 30 days (2904)
Last 365 days (32772)
2025 (27242)
2024 (37541)
2023 (42317)
2022 (53640)
2021 (58382)
2020 (57175)
2019 (50554)
2018 (38491)
2017 (36231)
2016 (36689)
2015 (42520)
2014 (36467)
2013 (32468)
2012 (34183)
2011 (34352)
2010 (33552)
Location
Africa (1160)
Alabama (80)
Alaska (7)
Arizona (284)
Arkansas (14)
Asia (47810)
Australia (8354)
California (9651)
Canada (2901)
China (937)
Colorado (403)
Connecticut (429)
Delaware (271)
Europe (109874)
Florida (1434)
Georgia (315)
Hawaii (3)
Idaho (66)
Illinois (804)
India (52)
Indiana (471)
Iowa (20)
Japan (333)
Kansas (125)
Kentucky (38)
Louisiana (21)
Maine (78)
Maryland (1294)
Massachusetts (7230)
Michigan (305)
Minnesota (571)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (109)
New Hampshire (79)
New Jersey (2697)
New Mexico (32)
New York (2627)
North Carolina (1397)
North Dakota (10)
Northern California (4454)
Ohio (303)
Oklahoma (22)
Oregon (41)
Pennsylvania (2002)
Puerto Rico (20)
Rhode Island (42)
South America (1544)
South Carolina (51)
South Dakota (1)
Southern California (3695)
Tennessee (147)
Texas (1506)
United States (35488)
Utah (286)
Virginia (238)
Washington D.C. (84)
Washington State (819)
West Virginia (4)
Wisconsin (96)
Wyoming (1)
803,286 Results for "the michael j fox foundation for parkinson s research".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease
August 6, 2025
·
1 min read
Business
MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).
June 18, 2024
·
4 min read
Pharm Country
Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research
Kannalife Sciences, Inc. is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research.
June 25, 2024
·
4 min read
Press Releases
The Michael J. Fox Foundation Expands Landmark Parkinson’s Research Study toward Better Treatments and Prevention
April 30, 2025
·
10 min read
Pharm Country
Michael J. Fox Foundation Funds Projects to Speed Development of Quantitative Biomarkers for Parkinson’s Disease
The Michael J. Fox Foundation for Parkinson’s Research announced $9.75 million in total awards to five research teams working on tools to biologically measure and track the progression of Parkinson’s disease from its earliest detection through more advanced stages.
May 30, 2024
·
6 min read
Press Releases
ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense
March 4, 2025
·
7 min read
Press Releases
Montara Therapeutics to Develop Novel Treatments Using the BrainOnly™ Platform with Grant from The Michael J. Fox Foundation
May 21, 2025
·
4 min read
Press Releases
NeuroDex Inc. Receives Grant from The Michael J. Fox Foundation to Advance Biomarker Research for Parkinson’s Disease
November 13, 2024
·
1 min read
Genetown
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research, a non-profit organization dedicated to finding a cure for Parkinson’s disease, announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA gene.
January 23, 2024
·
7 min read
Genetown
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.
March 5, 2024
·
5 min read
1 of 80,329
Next
